Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 29Terminated 5Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1CNS 1

Conditions

Pathologic Complete Response 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 184Carboplatin 132Cisplatin 102Paclitaxel 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 67Docetaxel 55atezolizumab 51Cyclophosphamide 49Bevacizumab 49Dexamethasone 45Capecitabine 45Oxaliplatin 42130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 37Prednisone 32osimertinib 31olaparib 29venetoclax 28fludarabine 28Leucovorin 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Epitopoietic Research Corporation

Phase 2 Active not recruiting
84 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡